Cynata Therapeutics Limited (CYP.AX)
AUD 0.2
(5.41%)
AUD 0.2
(5.41%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 1.17 Million AUD | -48.19% |
| 2023 | 2.26 Million AUD | -12.66% |
| 2022 | 2.58 Million AUD | 61.57% |
| 2021 | 1.6 Million AUD | 132.23% |
| 2020 | 689.73 Thousand AUD | -46.04% |
| 2019 | 1.27 Million AUD | 71.32% |
| 2018 | 746.14 Thousand AUD | 91.52% |
| 2017 | 389.59 Thousand AUD | -12.92% |
| 2016 | 447.37 Thousand AUD | 19.18% |
| 2015 | 375.39 Thousand AUD | 426.53% |
| 2014 | 71.29 Thousand AUD | -52.37% |
| 2013 | 149.7 Thousand AUD | -8.21% |
| 2012 | 163.08 Thousand AUD | -33.68% |
| 2011 | 245.92 Thousand AUD | -22.37% |
| 2010 | 316.81 Thousand AUD | -30.87% |
| 2009 | 458.25 Thousand AUD | 292.08% |
| 2008 | 116.87 Thousand AUD | -20.58% |
| 2007 | 147.16 Thousand AUD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 1.18 Million AUD | 0.0% |
| 2024 Q4 | 1.17 Million AUD | 0.0% |
| 2024 FY | 1.17 Million AUD | -48.19% |
| 2023 FY | 2.26 Million AUD | -12.66% |
| 2023 Q4 | 2.26 Million AUD | 0.0% |
| 2023 Q2 | 1.47 Million AUD | 0.0% |
| 2022 Q2 | 1.65 Million AUD | 0.0% |
| 2022 FY | 2.58 Million AUD | 61.57% |
| 2022 Q4 | 2.58 Million AUD | 0.0% |
| 2021 Q2 | 1.01 Million AUD | 0.0% |
| 2021 Q4 | 1.6 Million AUD | 0.0% |
| 2021 FY | 1.6 Million AUD | 132.23% |
| 2020 Q4 | 689.73 Thousand AUD | 0.0% |
| 2020 FY | 689.73 Thousand AUD | -46.04% |
| 2020 Q2 | 1.09 Million AUD | 0.0% |
| 2019 Q2 | 575.13 Thousand AUD | 0.0% |
| 2019 FY | 1.27 Million AUD | 71.32% |
| 2019 Q4 | 1.27 Million AUD | 0.0% |
| 2018 FY | 746.14 Thousand AUD | 91.52% |
| 2018 Q2 | 334.88 Thousand AUD | 0.0% |
| 2018 Q4 | 746.14 Thousand AUD | 0.0% |
| 2017 Q2 | 248.77 Thousand AUD | 0.0% |
| 2017 Q4 | 389.59 Thousand AUD | 0.0% |
| 2017 FY | 389.59 Thousand AUD | -12.92% |
| 2016 Q2 | 710.57 Thousand AUD | 0.0% |
| 2016 Q4 | 447.37 Thousand AUD | 0.0% |
| 2016 FY | 447.37 Thousand AUD | 19.18% |
| 2015 Q2 | 206.96 Thousand AUD | 0.0% |
| 2015 Q4 | 375.39 Thousand AUD | 0.0% |
| 2015 FY | 375.39 Thousand AUD | 426.53% |
| 2014 FY | 71.29 Thousand AUD | -52.37% |
| 2014 Q2 | 225.97 Thousand AUD | 0.0% |
| 2014 Q4 | 71.29 Thousand AUD | 0.0% |
| 2013 Q2 | 121.75 Thousand AUD | 0.0% |
| 2013 FY | 149.7 Thousand AUD | -8.21% |
| 2013 Q4 | 149.7 Thousand AUD | 0.0% |
| 2013 Q3 | 149.7 Thousand AUD | 22.96% |
| 2013 Q1 | 121.75 Thousand AUD | -25.35% |
| 2012 FY | 163.08 Thousand AUD | -33.68% |
| 2012 Q4 | 163.08 Thousand AUD | 0.0% |
| 2011 Q4 | 245.92 Thousand AUD | 0.0% |
| 2011 FY | 245.92 Thousand AUD | -22.37% |
| 2010 FY | 316.81 Thousand AUD | -30.87% |
| 2010 Q4 | 316.81 Thousand AUD | 0.0% |
| 2009 FY | 458.25 Thousand AUD | 292.08% |
| 2009 Q4 | 458.25 Thousand AUD | 0.0% |
| 2008 Q4 | 116.87 Thousand AUD | 0.0% |
| 2008 FY | 116.87 Thousand AUD | -20.58% |
| 2007 FY | 147.16 Thousand AUD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AdAlta Limited | 3.54 Million AUD | 66.943% |
| Acrux Limited | 5.68 Million AUD | 79.408% |
| Race Oncology Limited | 1.91 Million AUD | 38.894% |
| Biome Australia Limited | 5.37 Million AUD | 78.206% |
| Botanix Pharmaceuticals Limited | 3.73 Million AUD | 68.622% |
| BTC Health Limited | 203.94 Thousand AUD | -474.193% |
| Chimeric Therapeutics Limited | 12.8 Million AUD | 90.853% |
| CSL Limited | 27.88 Billion AUD | 99.996% |
| Clarity Pharmaceuticals Ltd | 8.33 Million AUD | 85.945% |
| Clinuvel Pharmaceuticals Limited | 28.11 Million AUD | 95.834% |
| EZZ Life Science Holdings Limited | 4.22 Million AUD | 72.31% |
| Hexima Limited | 248.67 Thousand AUD | -370.927% |
| Immutep Limited | 10.97 Million AUD | 89.334% |
| Memphasys Limited | 5.59 Million AUD | 79.06% |
| Neuren Pharmaceuticals Limited | 42.76 Million AUD | 97.262% |
| Noxopharm Limited | 1.28 Million AUD | 9.123% |
| Prescient Therapeutics Limited | 2.32 Million AUD | 49.644% |
| Radiopharm Theranostics Limited | 44.68 Million AUD | 97.379% |
| Starpharma Holdings Limited | 8.69 Million AUD | 86.537% |
| Tissue Repair Ltd | 1.35 Million AUD | 13.313% |
| Biotron Limited | 737.5 Thousand AUD | -58.785% |
| Alterity Therapeutics Limited | 5.42 Million AUD | 78.416% |
| Anatara Lifesciences Ltd | 306.84 Thousand AUD | -281.639% |
| Bio-Gene Technology Limited | 368.44 Thousand AUD | -217.836% |
| Zelira Therapeutics Limited | 9.35 Million AUD | 87.484% |
| Patrys Limited | 691.36 Thousand AUD | -69.383% |
| Orthocell Limited | 22.08 Million AUD | 94.697% |
| Imugene Limited | 33.14 Million AUD | 96.467% |
| PYC Therapeutics Limited | 10.18 Million AUD | 88.501% |
| Proteomics International Laboratories Limited | 1.62 Million AUD | 27.976% |
| Arovella Therapeutics Limited | 2.05 Million AUD | 43.06% |
| Nanollose Limited | 465.64 Thousand AUD | -151.492% |
| Invex Therapeutics Ltd | 431.63 Thousand AUD | -171.31% |
| NeuroScientific Biopharmaceuticals Limited | 85.68 Thousand AUD | -1266.73% |
| Amplia Therapeutics Limited | 3.42 Million AUD | 65.827% |
| Island Pharmaceuticals Limited | 1.04 Million AUD | -11.996% |
| Nyrada Inc. | 855.63 Thousand AUD | -36.864% |
| Telix Pharmaceuticals Limited | 249.39 Million AUD | 99.53% |
| Dimerix Limited | 13.89 Million AUD | 91.571% |
| PharmAust Limited | 896.6 Thousand AUD | -30.61% |
| AnteoTech Limited | 4.07 Million AUD | 71.264% |
| Paradigm Biopharmaceuticals Limited | 3.58 Million AUD | 67.329% |
| Recce Pharmaceuticals Ltd | 15.89 Million AUD | 92.632% |
| Avecho Biotechnology Limited | 941.54 Thousand AUD | -24.377% |
| Actinogen Medical Limited | 1.61 Million AUD | 27.505% |
| Immuron Limited | 2.84 Million AUD | 58.773% |
| Argenica Therapeutics Limited | 2.42 Million AUD | 51.743% |